There are 2789 resources available
1327P - Impact of bone targeted agents (BTA) in advanced non-small cell lung cancer (aNSCLC) patients (pts) with high bone tumor burden (HBTB) treated with PD(L)1 inhibitors (ICIs)
Presenter: Sara Manglaviti
Session: ePoster Display
1328P - Outcomes from local consolidative therapy and immune checkpoint inhibitors in metastatic non-small cell lung cancer
Presenter: Lingzhi Hong
Session: ePoster Display
1329P - A single-arm, open-label, multi-center, phase I study of HA121-28 in patients with advanced solid tumors
Presenter: Hongyun Zhao
Session: ePoster Display
1330P - Second-line nintedanib + docetaxel for patients with lung adenocarcinoma after first-line chemo-immunotherapy treatment: Updated efficacy and safety results from VARGADO Cohort C
Presenter: Christian Grohé
Session: ePoster Display
1331P - Open-label phase I/II study evaluating the tolerability and anti-tumor activity of selinexor (SEL) and docetaxel (DTX) in non-small cell lung cancer (NSCLC)
Presenter: Alona Zer
Session: ePoster Display
1332P - A randomized phase II trial of standard versus low-dose nab-paclitaxel for previously treated advanced non-small cell lung cancer (JMTO LC14-01)
Presenter: Susumu Takeuchi
Session: ePoster Display
1333P - Dose and schedule modifications of carboplatin plus nab-paclitaxel for elderly patients with squamous non-small cell lung cancer from the CAPITAL study
Presenter: Go Saito
Session: ePoster Display
1335P - Updated results from a phase I/II study of anlotinib plus docetaxel vs docetaxel as second-line treatment of advanced non-small cell lung cancer (NSCLC)
Presenter: Yong Fang
Session: ePoster Display